References

  1. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340: 115–126.
  2. Shah PK (2003) Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41 (4 Suppl S): S15S–S22S.
  3. Binder CJ et al. (2002) Innate and acquired immunity in atherogenesis. Nat Med 8: 1218–1226.
  4. Hansson GK et al. (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91: 281–291.
  5. Nilsson J et al. (2005) Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 25: 18–28.
  6. Frostegard J (2002) Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev 1: 233–237.
  7. Tornvall P et al. (2003) Autoantibodies against modified low-density lipoproteins in coronary artery disease. Atherosclerosis 167: 347–353.
  8. Perschinka H et al. (2003) Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol 23: 1060–1065.
  9. Xu Q et al. (1993) Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341: 255–259.
  10. Stemme S et al. (1995) T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92: 3893–3897.
  11. Afek A et al. (2000). Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 14: 115–121.
  12. Xu Q et al. (1992). Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 12: 789–799.
  13. George J et al. (1998) Induction of early atherosclerosis in LDL-receptor deficient mice immunized with β2 glycoprotein I. Circulation 11: 1108–1115.
  14. Palinski W et al. (1995) Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 92: 821–825.
  15. Ameli S et al. (1996) Effect of immunization with homologous LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16: 1074–1079.
  16. Nilsson J et al. (1997) Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon in hypercholesterolemic rabbits. J Am Coll Cardiol 30: 1886–1891.
  17. Freigang S et al. (1998) Immunization of LDL receptor deficient mice with homologous malondialdehyde modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 18: 1972–1982.
  18. Zhou X et al. (2001) LDL immunization induces T-cell dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21: 108–114.
  19. Chyu KY et al. (2004) Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (–/–) mice. Atherosclerosis 176: 27–35.
  20. Fong LG et al. (1987) Non enzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 12: 1466–1477.
  21. Hulthe J et al. (2001). Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21: 101–107.
  22. Fukumoto M et al. (2000) Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 20: 703–707.
  23. Hulthe J et al. (2001) Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A2. Arterioscler Thromb Vasc Biol 21: 269–274.
  24. alinski W and Witztum JL (2000) Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 247: 371–380.
  25. Fredrikson GN et al. (2003) Identification of immune responses against aldehyde-modified peptide sequences in ApoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 23: 872–878.
  26. Fredrikson GN et al. (2003) Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 23: 879–884.
  27. Reyes OS et al. (2002) Immunization with a novel human Apo B100 related peptide reduces atherosclerosis and inflammation in Apo E null mice. J Am Coll Cardiol 39 (Suppl A): S240A.
  28. Schipou A et al. (2004) Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 110: 2047–2052.
  29. Palinski et al. (1994) ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. ATVB 14: 605-616.
  30. Chyu KY, et al. (2005) Immunization Using an Apo B-100 Related Epitode Reduces Atherosclerosis and Plaque Inflammation in Hypercholesterolemic Apo E (-/-) Mice. BBRC 338; 1982-1989
  31. Fredrikson GN, et al. (2007) Association Between IgM Against Aldehyde-Modified Peptide in Apolipoprotein B-100 and Progression of Carotid Disease. Stroke 38:1495-1500
  32. Sjögren P, et al. (2008) High Plasma Concentrations of Autoantibodies against Native Peptide 210 of ApoB-100 are Related to Less Coronary Atherosclerosis and Lower Risk of Myocardial Infarction. Eur Heart J 29:2218-2226.
  33. Fredrikson GN, et al. (2005) Atheroprotective Immunization with MDA-modified ApoB-100 Peptide Sequences is Associated with Activation of Th2 Specific Antibody Expression. Autoimmunity 38:17-179.
  34. Hansson G and Libby P. (2006) The Immune Response in Atherosclerosis: a Double Edged Sword. Nature Reviews Immunology 6:508-519.
  35. Anand DV, et al (2006) Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. European Heart Journal 27; 713-721.
  36. Fredrikson GN, et al. (2007) Autoantibody against the amino acid sequence 661-680 in apoB-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 194; e188-e192.
  37. Fredrikson GN, et al. (2009) Associations between autoantibodies against apoB-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia (in the press).

Back to top of page